Palisade Bio (PALI) Expected to Announce Earnings on Monday

Palisade Bio (NASDAQ:PALI) is expected to announce its Q1 2026 results after the market closes on Monday, May 11th. Analysts expect the company to announce earnings of ($0.04) per share for the quarter. Interested persons are encouraged to explore the company’s upcoming Q1 2026 earning overview page for the latest details on the call scheduled for Monday, May 11, 2026 at 4:00 PM ET.

Palisade Bio Trading Up 1.3%

PALI stock traded up $0.03 during trading on Monday, hitting $2.02. 283,209 shares of the company’s stock were exchanged, compared to its average volume of 4,353,936. The business has a 50-day moving average price of $1.96 and a two-hundred day moving average price of $1.92. The stock has a market capitalization of $337.35 million, a price-to-earnings ratio of -0.95 and a beta of 1.52. Palisade Bio has a 52-week low of $0.53 and a 52-week high of $2.86.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on PALI shares. HC Wainwright started coverage on Palisade Bio in a research note on Thursday, March 26th. They issued a “buy” rating and a $7.00 price objective for the company. Weiss Ratings reiterated a “sell (e+)” rating on shares of Palisade Bio in a research note on Thursday, January 22nd. Wolfe Research began coverage on Palisade Bio in a research note on Thursday, April 9th. They set an “outperform” rating and a $7.00 price target for the company. B. Riley Financial began coverage on Palisade Bio in a research note on Friday, January 9th. They set a “buy” rating and a $7.00 price target for the company. Finally, Wall Street Zen upgraded Palisade Bio from a “sell” rating to a “hold” rating in a research note on Saturday, February 28th. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $10.20.

Institutional Trading of Palisade Bio

Large investors have recently bought and sold shares of the company. Cetera Investment Advisers acquired a new stake in Palisade Bio in the fourth quarter valued at $25,000. Schonfeld Strategic Advisors LLC acquired a new stake in Palisade Bio in the fourth quarter valued at $26,000. Virtu Financial LLC acquired a new stake in Palisade Bio in the fourth quarter valued at $28,000. Atom Investors LP acquired a new stake in Palisade Bio in the fourth quarter valued at $33,000. Finally, Barclays PLC acquired a new stake in Palisade Bio in the fourth quarter valued at $35,000. Institutional investors and hedge funds own 11.79% of the company’s stock.

Palisade Bio Company Profile

Palisade Bio, Inc is a clinical‐stage biotechnology company focused on pioneering localized immunotherapies for the treatment of cancer and inflammatory diseases. The company leverages a proprietary prodrug platform designed to activate therapeutic agents selectively within the tumor microenvironment or sites of inflammation. Its core strategy centers on stimulating the innate immune system via toll‐like receptor 9 (TLR9) agonism to drive targeted immune responses while minimizing systemic exposure and toxicity.

The company’s lead product candidate, PDS0108, is an intratumoral TLR9 agonist prodrug currently in Phase 1/2 clinical trials for patients with advanced solid tumors.